Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clostridium butyricum plus atezolizumab as adjuvant therapy in resected PD-L1-positive NSCLC
ChiCTR2300069317Phase 4Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clostridium butyricum and atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Change in gut microbiota from baseline to 3 months after start of study treatment. Started Mar 2023; status: recruiting.
02
Drugs
clostridium butyricumatezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300069317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069317.